Ascorbic acid attenuates obesity induced myogenic impairment in C2C12 cells

Life Sciences · Published 2026-08-01 · DOI 10.1016/j.lfs.2026.124612

Authors (4)

Joel Rimson Pinto, Deepika Bhat. K, Bipasha Bose, Sudheer Shenoy P.

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Pinto, J., K, D., Bose, B., et al. (2026). Ascorbic acid attenuates obesity induced myogenic impairment in C2C12 cells. Life Sciences. https://doi.org/10.1016/j.lfs.2026.124612

Related articles

• RPS20 phosphorylation acts as a molecular switch to integrate inflammatory and oxidative stress signals in sepsis · Life Sciences · 2026 · Same journal
• Identification of JEV capsid interacting domain(s) with host protein(s): Novel target for developing anti-JEV therapeutics · Life Sciences · 2026 · Same journal
• Overactivated bradykinin–B2 receptor promotes type a aortic dissection by inducing endothelial dysfunction: Therapeutic effect of icatibant · Life Sciences · 2026 · Same journal
• Local lymphatic circulation disorder: A key promoter of tissue inflammation and organ fibrosis · Life Sciences · 2026 · Same journal
• Slc26a9 guards gastric mucosa against portal hypertension by reducing ER stress-induced apoptosis · Life Sciences · 2026 · Same journal
• The next-generation virtual cell: From spatiotemporal transcriptomic modeling to closed-loop target discovery in complex diseases · Life Sciences · 2026 · Same journal
• Soluble PD-1 drives renal fibrosis in CKD by disrupting immune homeostasis: Therapeutic mitigation via a targeted sPD-1 sequestration strategy · Life Sciences · 2026 · Same journal
• CCL28 ameliorates chronic liver damage associated with the recruitment of immunosuppressive IgA antibody-secreting cells in mice · Life Sciences · 2026 · Same journal
• Mertk-dependent immune regulation is required for the therapeutic effects of fecal microbiota transplantation in a mouse model of constipation-predominant irritable bowel syndrome · Life Sciences · 2026 · Same journal
• Patient-derived cornea organoids as drug repurposing models for aniridia-associated keratopathy · Life Sciences · 2026 · Same journal